CARB-X
CARB-X is a biopharmaceutical business enterprise that specializes in biotechnology, antibiotics, vaccines, fast diagnostics.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed CARB-X Information
Geographic Data
Address: 771e Commonwealth Avenue
City: Boston
State: MA
Zip: 02215
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$370M
Social
Twitter
Linkedin
Crunchbase
Metrics
1,665,716Website Global Rank
14,258Website Monthly Traffic
Twitter Followers
Description
Accelerate a diverse portfolio of at least 20 high-quality antibacterial products towards clinical development leveraging $250 million in BARDA funds with matching funds from the Wellcome Trust and the AMR Centre.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2020 | Module Innovations | Grant | 3.2M |
| 7/2017 | Debiopharm Group | Grant | 2.6M |
| 5/2018 | Melinta Therapeutics | Grant | 6.2M |
| 8/2020 | Evotec | Grant | 2.9M |
| 6/2018 | BUGWORKS Research | Grant | - |
| 5/2020 | Day Zero Diagnostics | Grant | 6.2M |
| 6/2021 | BioVersys | Grant | 0 |
| 2/2021 | Institute for Molecular Bioscience | Grant | 2.2M |
| 4/2021 | GenomeKey | Grant | 9.5M |
| 6/2019 | Vaxcyte | Grant | 1.6M |
| 5/2019 | Debiopharm Group | Grant | 2.1M |
| 3/2017 | PROTEUS | Grant | 1.1M |
| 9/2019 | TAXIS Pharmaceuticals | Grant | 3.2M |
| 5/2021 | Basilea Pharmaceutica | Grant | 2.7M |
| 5/2021 | SpeeDx | Grant | 1.8M |
| 3/2017 | Spero Therapeutics | Grant | 6.8M |
| 12/2019 | Vedanta Biosciences | Grant | 5.8M |
| 2/2019 | Recida Therapeutics | Grant | 4.4M |
| 4/2021 | Jenner Institute | Grant | 2M |
| 3/2018 | Specific Diagnostics | Grant | 3.4M |
| 1/2021 | Lumen Bioscience | Grant | 14.5M |
| 11/2019 | Techulon | Grant | 785k |
| 4/2021 | Novel Microdevices | Grant | 13.8M |
| 3/2018 | Shionogi | Grant | 7.6M |
| 1/2020 | University of Queensland | Grant | 10.9M |
| 7/2018 | Summit Therapeutics | Grant | 4.5M |
| 5/2018 | Talis Biomedical | Grant | 8.6M |
| 3/2017 | ContraFect | Grant | 2.1M |
| 10/2017 | Seres Therapeutics | Grant | 5.6M |
| 3/2019 | ContraFect | Grant | 6.9M |
| 10/2022 | Day Zero Diagnostics | Grant | 8.2M |
| 11/2019 | Venatorx Pharmaceuticals | Grant | 4.1M |
| 3/2017 | University of Edinburgh | Grant | 3.6M |
| 10/2020 | GangaGen | Grant | 2.5M |
| 12/2017 | Inhibrx | Grant | 6M |
| 4/2018 | Idorsia | Grant | 9M |
| 3/2017 | Redx Pharma | Grant | 1M |
| 12/2020 | Polyphor | Grant | 2.3M |
| 10/2017 | Entasis Therapeutics | Grant | 3.8M |
| 3/2018 | T2 Biosystems | Grant | 2M |
| 7/2017 | Antabio | Grant | 8.9M |
| 2/2020 | Lytica Therapeutics | Grant | 5.3M |
| 12/2020 | Helmholtz Centre for Infection Research | Grant | 8.8M |
| 8/2019 | Vaxxilon | Grant | 1.4M |
| 4/2017 | Tetraphase Pharmaceuticals | Grant | 4M |
| 6/2020 | Amicrobe | Grant | 4.6M |
| 6/2020 | Institute for Molecular Bioscience | Grant | 10.9M |
| 1/2019 | ContraFect | Grant | 2.3M |
| 7/2017 | Venatorx Pharmaceuticals | Grant | 9.4M |
| 5/2020 | Microbion | Grant | 17.1M |
| 1/2020 | Antabio | Grant | 4.4M |
| 7/2017 | Achaogen | Grant | 14.6M |
| 11/2017 | Integrated BioTherapeutics | Grant | 8.3M |
| 7/2019 | Integrated BioTherapeutics | Grant | 1.6M |
| 10/2019 | Trellis Bioscience | Grant | 3.2M |
| 12/2019 | HelixBind | Grant | 4M |
| 2/2020 | Facile Therapeutics | Grant | 1.3M |
| 2/2019 | Polyphor | Grant | 5.6M |
| 10/2020 | Polyphor | Grant | 18.4M |
| 8/2021 | Vaxcyte | Grant | 3.2M |
| 3/2017 | Oppilotech | Grant | 120k |
| 6/2021 | Accelerate Diagnostics | Grant | 0 |
| 5/2021 | Summit Therapeutics | Grant | 0 |
| 9/2020 | GlaxoSmithKline | Grant | 7.5M |
| 2/2021 | University of Queensland | Grant | 2.2M |
| 11/2017 | Vedanta Biosciences | Grant | 5.4M |
| 4/2021 | Phico Therapeutics | Grant | 18.2M |
| 10/2020 | Cellics Therapeutics | Grant | 3.9M |
| 2/2018 | Curza | Grant | 4M |
| 12/2020 | Vaxcyte | Grant | 2.7M |
| 2/2020 | Pattern Bioscience | Grant | 6.8M |
| 2/2020 | Peptilogics | Grant | 2.6M |
| 3/2017 | Cidara Therapeutics | Grant | 6.9M |
| 7/2018 | scibac | Grant | 3.8M |
| 8/2017 | EligoChem | Grant | 4.8M |
| 5/2019 | Oxford Drug Design | Grant | 2.5M |
| 11/2020 | Locus Biosciences | Grant | 12.5M |
| 5/2021 | SNIPR Biome | Grant | 10.2M |
| 10/2019 | BioVersys | Grant | 8.9M |
| 1/2019 | Forge Therapeutics | Grant | 5.7M |
| 4/2022 | Clarametyx Biosciences | Grant | 3.9M |
| 3/2018 | MicuRx Pharmaceuticals | Grant | 5.2M |
| 6/2019 | Vaxdyn | Grant | 7.3M |
| 3/2021 | Affinivax | Grant | 22M |
| 8/2020 | MicuRx Pharmaceuticals | Grant | 7.8M |
| 9/2019 | Procarta Biosystems | Grant | 9.2M |
| 3/2018 | Zikani Therapeutics | Grant | 6.8M |
| 7/2017 | Iterum Therapeutics | Grant | 1.5M |
| 3/2018 | Helixbind | Grant | 2M |
| 7/2020 | ContraFect | Grant | 18.9M |
| 3/2017 | Entasis Therapeutics | Grant | 6.3M |
| 9/2020 | Mutabilis | Grant | 6.4M |
| 4/2021 | Baebies | Grant | 0 |
| 3/2021 | GlaxoSmithKline | Grant | 18M |
| 3/2017 | Forge Therapeutics | Grant | 8.8M |
| 10/2017 | Amicrobe | Grant | 2.5M |
| 6/2020 | Eligo Bioscience | Grant | 7M |
| 11/2020 | Clarametyx Biosciences | Grant | 14.2M |
| 2/2021 | Avails Medical | Grant | 2.5M |
| 1/2020 | Centauri Therapeutics | Grant | 1.4M |
| 4/2017 | Microbiotix | Grant | 2.9M |
| 7/2020 | Vaxdyn | Grant | 892k |
| 4/2018 | Achaogen | Grant | 12M |
| 4/2022 | Clarametyx Biosciences | Grant | 0 |
| 8/2021 | Vaxcyte | Grant | 0 |
| 6/2021 | Accelerate Diagnostics | Grant | 0 |
| 6/2021 | BioVersys | Grant | 0 |
| 5/2021 | SNIPR Biome | Grant | 0 |
| 5/2021 | Basilea Pharmaceutica | Grant | 0 |
| 5/2021 | Summit Therapeutics | Grant | 0 |
| 5/2021 | SpeeDx | Grant | 0 |
| 4/2021 | GenomeKey | Grant | 0 |
| 4/2021 | Baebies | Grant | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
